Amy E. Juedes

Array ( [id] => 15020795 [patent_doc_number] => 20190321402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => NK CELLS FOR USE WITH ANITBODIES IN CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/376446 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16376446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649473 [patent_doc_number] => 20190231865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) [patent_app_type] => utility [patent_app_number] => 16/372832 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16372832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578627 [patent_doc_number] => 20190216922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => ENHANCING THE T-CELL STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS IN VITRO AND IN VIVO AND ITS USE IN VACCINATION [patent_app_type] => utility [patent_app_number] => 16/369209 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16369209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253757 [patent_doc_number] => 20200263131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => Methods to Expand a T Regulatory Cell Master Cell Bank [patent_app_type] => utility [patent_app_number] => 16/366004 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578601 [patent_doc_number] => 20190216909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => MEANS AND METHODS FOR ACTIVE CELLULAR IMMUNOTHERAPY OF CANCER BY USING TUMOR CELLS KILLED BY HIGH HYDROSTATIC PRESSURE AND DENDRITIC CELLS [patent_app_type] => utility [patent_app_number] => 16/365027 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16365027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527693 [patent_doc_number] => 20200056152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE [patent_app_type] => utility [patent_app_number] => 16/361852 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897509 [patent_doc_number] => 20190292520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHOD OF ENHANCING PERSISTENCE OF ADOPTIVELY INFUSED T CELLS [patent_app_type] => utility [patent_app_number] => 16/361043 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293635 [patent_doc_number] => 20190389953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease [patent_app_type] => utility [patent_app_number] => 16/356940 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612235 [patent_doc_number] => 20210030888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/978539 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -100 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612235 [patent_doc_number] => 20210030888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/978539 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -100 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16769784 [patent_doc_number] => 10980867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Regulatory T cell epitopes, compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 16/291658 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 22055 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464707 [patent_doc_number] => 20190183993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/291372 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14567401 [patent_doc_number] => 20190211307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/289095 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389852 [patent_doc_number] => 20230158070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => COMBINATION COMPRISING ALLOGENEIC IMMUNE CELLS DEFICIENT FOR AN ANTIGEN PRESENT ON BOTH T-CELLS AND PATHOLOGICAL CELLS AND THERAPEUTIC ANTIBODY AGAINST SAID ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/965834 [patent_app_country] => US [patent_app_date] => 2019-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309689 [patent_doc_number] => 20190144548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Depletion of Plasmacytoid Dendritic Cells [patent_app_type] => utility [patent_app_number] => 16/260490 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16260490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657699 [patent_doc_number] => 20210054335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/977320 [patent_app_country] => US [patent_app_date] => 2019-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20185936 [patent_doc_number] => 12397036 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Peptide exchange protein [patent_app_type] => utility [patent_app_number] => 16/964695 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 22 [patent_no_of_words] => 21026 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20185936 [patent_doc_number] => 12397036 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Peptide exchange protein [patent_app_type] => utility [patent_app_number] => 16/964695 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 22 [patent_no_of_words] => 21026 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671383 [patent_doc_number] => 20210060146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => DENDRITIC CELL VACCINATION IN PARALLEL TO CHEMOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/964863 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467819 [patent_doc_number] => 20190185552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1 [patent_app_type] => utility [patent_app_number] => 16/233738 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233738 [rel_patent_id] =>[rel_patent_doc_number] =>)